Amgen and GlaxoSmithKline entered into a collaboration under which the companies will share commercialization of Amgen’s monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand and Mexico, once approved in these countries. Amgen will commercialize the drug for PMO and oncology in the U.S. and Canada and for all oncology indications in Europe and specified markets. GSK will register and commercialize denosumab for all indications in China, Br...